Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 1998

View Archived Issues

Lilly initiates pivotal trials with SkyePharma formulation

Pharmacokinetics of capecitabine affected by food

Novel prokinetic agent, R-93877, accelerates upper gut and colonic transit in humans

AutoImmune: Q1 1998 highlights

Chiroscience prepares new peptidyl inhibitors of MMPs and TNF production

New treatments for Alzheimer's disease in the pipeline at Schering-Plough

Selective thrombin inhibitors described by Merck scientists

Celgene claims agents for reducing cytokine levels

REFAC Biochemics and NYHQ will evaluate Pyloricide for the treatment of peptic ulcers

Bayer reports on new studies of nifedipine

Digene: Q3 1998 highlights

AVI BioPharma: Q1 1998 highlights

DISC HSV reported to be safe and immunogenic in phase I trials

New evidence supports the role of genetics in drug addiction

Company Profile: Vascular Therapeutics

Promising phase I/II findings in NSCLC reported for INGN-201 at ASCO

Cheung Laboratories name change finalized

Profile of eplerenone, a novel aldosterone antagonist from Searle

Interim results reported for Zenapax combination in kidney transplantation

Preliminary clinical results indicate good tolerability for LGD-1550 in cancer patients

T-cell gene therapy developed at Cell Genesys markedly reduces TAG-72 blood levels

Targeted Genetics' E1A gene therapy headed for phase II trials in head and neck cancer

S-Nitrosocaptopril combines NO-donor and ACE-inhibitor effects in a single molecule

PNU-142721, a more potent NNRTI in development at Pharmacia & Upjohn

DEHOP phase II data discussed at Digestive Disease Week

Herceptin: promising phase III results reported at ASCO

Alcon's diclofenac sodium approved for ocular inflammation indication

Vanguard Medica and SmithKline Beecham terminate frovatriptan collaboration

NO-NSAIDs retain antiinflammatory/analgesic potency, with fewer GI side effects

Allergene acquires rights to ALG-889

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...